A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies

LESSONS LEARNED: The novel therapeutic vaccine hVEGF(26–104)/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF(26–104)/RFASE failed to induce seroconversion against native hVEGF(165) and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VE...

Descripción completa

Detalles Bibliográficos
Autores principales: Goedegebuure, Ruben S.A., Wentink, Madelon Q., van der Vliet, Hans J., Timmerman, Peter, Griffioen, Arjan W., de Gruijl, Tanja D., Verheul, Henk M.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873342/
https://www.ncbi.nlm.nih.gov/pubmed/33105058
http://dx.doi.org/10.1002/onco.13576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873342/
https://www.ncbi.nlm.nih.gov/pubmed/33105058
http://dx.doi.org/10.1002/onco.13576

Ejemplares similares